Patrick Verheyen - 02 Jan 2025 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Director
Signature
/s/ Patrick Verheyen by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
02 Jan 2025
Net transactions value
$0
Form type
4
Filing time
03 Jan 2025, 16:00:19 UTC
Previous filing
04 Jan 2024
Next filing
06 Jan 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +24,400 $0.000000 24,400 02 Jan 2025 Common Stock 24,400 $1.09 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
F2 This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date.